![[Rishi Pimentel, gChem]](https://cdn.sanity.io/images/0vv8moc6/pharmtech/16bc98940a34f0991f9ca5e7ccbfa6889fec078f-1634x909.jpg?w=350&fit=crop&auto=format)
|Videos|August 4, 2021
From Drug Substance to Drug Product: Integrated Solid Form Selection
Author(s)Lonza
What are some effective strategies for compressing development timelines and derisking the process along the way? The PharmTech-Lonza Tech Talks Series on Integrated Services includes a 12-minute discussion of integrated drug substance form selection and optimization to drug product with Michael Grass, PhD, head of solid form services at Lonza.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
![[Rishi Pimentel, gChem]](https://cdn.sanity.io/images/0vv8moc6/pharmtech/01d391920288b8bd8b751988988b5a6544a6ddaa-1629x908.jpg?w=350&fit=crop&auto=format)
![[Nigel Langley]](https://cdn.sanity.io/images/0vv8moc6/pharmtech/e2c0137d8224aaa1f14c0f1af43b58d21f4541dd-1768x904.jpg?w=350&fit=crop&auto=format)
Trending on Pharmaceutical Technology
1
Behind the Headlines Episode 28: Navigating FDA Shakeups and Obesity Drug Wars
2
AAPS PharmSci 360 2025: The Role of LC–MS in Bioanalysis
3
Why Investment Strategies Matter for Advancing Pharmaceutical Technologies
4
New Dosage Forms and Delivery Systems Driving 505(b)(2) Success
5
